Skip to main content

Advertisement

SpringerLink
Log in

Update on hormonal contraception and bone density

  • Published:
Reviews in Endocrine and Metabolic Disorders Aims and scope Submit manuscript

Abstract

Combination hormonal contraception and progestin-only contraception (including depot medroxyprogesterone acetate [DMPA]) are effective and convenient forms of reversible contraception that millions of women use worldwide. In recent years, observations of reduced bone mineral density in current users of these methods have led to concerns that this hormone-induced bone loss might translate into long-term increased fracture risk. Special focus has been placed on adolescent users who have not yet attained their peak bone mass as well as perimenopausal users. In 2004, the FDA added a black box warning to DMPA package labeling warning of the risk of significant bone loss and cautioning against long-term use (>2 years). This article reviews evidence on the use of hormonal contraception and its effect on bone density in adolescent, premenopausal, and perimenopausal populations. Recommendations from reproductive healthcare organizations are reviewed and clinical recommendations are provided.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Mosher WD, Jones J. Use of Contraception in the United States: 1982–2008. Vital and Health Statistics. Series 23, Number 29, May 2010.

  2. Trussell J. Contraceptive failure in the United States. Contraception. 2004;70:89–96.

    Article  PubMed  Google Scholar 

  3. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21:115–37.

    Article  PubMed  CAS  Google Scholar 

  4. Clarke BL, Khosla S. Female reproductive system and bone. Archives of Biochemistry and Biophysics. 2010;503:118–28.

    Article  PubMed  CAS  Google Scholar 

  5. Sirola J, Kroger H, Honkanen R, Jurvelin JS, Sandini L, Tuppurainen MT, et al. Factors affecting bone loss around menopause in women without HRT: a prospective study. Maturitas. 2003;45:159–67.

    Article  PubMed  Google Scholar 

  6. Boot AM, de Ridder MA, Pols HA, Krenning EP, de Muinck Keizer-Schrama SM. Bone mineral density in children and adolescents: relation to puberty, calcium intake, and physical activity. J Clin Endocrinol Metab. 1997;82:57–62.

    Article  PubMed  CAS  Google Scholar 

  7. Martins SL, Curtis KM, Glasier AF. Combined hormonal contraception and bone health: a systematic review. Contraception. 2006;73:445–69.

    Article  PubMed  CAS  Google Scholar 

  8. Castelo-Branco C, Vicente JJ, Pons F, Martinex de Osaba MJ, Casals E, Vanrell JA. Bone mineral density in young, hypothalamic olioamenorrheic women treated with oral contraceptives. J reprod Med. 2001;46:875–9.

    PubMed  CAS  Google Scholar 

  9. Hergenroeder AC, Smith EO, Shypailo R, Jones LA, Klish WJ, Ellis K. Bone mineral changes in young women with hypothalamic amenorrhea treated with oral contraceptives, medroxyprogesterone, or placebo over 12 months. Am J Obstet Gynecol. 1997;176:1017–25.

    Article  PubMed  CAS  Google Scholar 

  10. Rickenkund A, Carlstrom K, Ekblom B, Brismar TB, Von SB, Hirschberg AL. Effects of oral contraceptives on body composition and physical performance in female athletes. J Clin Endocrinal Metab. 2004;89:4364–70.

    Article  CAS  Google Scholar 

  11. Seeman E, Szmukler GI, Formica C, Tsalamandris C, Mestrovic R. Osteoporosis in anorexia nervosa: the influence of peak bone density, bone loss, oral contraceptive use, and exercise. J Bone Miner Res. 1992;7:1467–74.

    Article  PubMed  CAS  Google Scholar 

  12. Cromer BA, Lazebnik R, Rome E, Bonny A, Ziegler J, Debanne SM. Double-blinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception. Am J Obstet Gynecol. 2005;192:42–7.

    Article  PubMed  CAS  Google Scholar 

  13. Cundy T, Ames R, Horne A, Roberts H, Gamble G, Reid IR. A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate. J Clin Endocrinol Metab. 2003;88:78–81.

    Article  PubMed  CAS  Google Scholar 

  14. Doren M, Nilsson J, Johnell O. Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis. Hum Reprod. 2003;18:1737–46.

    Article  PubMed  CAS  Google Scholar 

  15. Watts NB, Ettinger B, LeBoff MS. Perspective: FRAX Facts. J Bone Min Research. 2009;24:975–9.

    Article  Google Scholar 

  16. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1995;332:767–73.

    Article  PubMed  CAS  Google Scholar 

  17. McClung MR. The relationship between bone mineral density and fracture risk. Curr Osteoporos Rep. 2005;3:57–63.

    Article  PubMed  Google Scholar 

  18. Hui SL, Slemenda CW, Johnston CC. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest. 1988;81:1804–9.

    Article  PubMed  CAS  Google Scholar 

  19. Grimes DA, Schulz KF. Surrogate end points in clinical research: hazardous to your health. Obstet Gynecol. 2005;105:1114–8.

    Article  PubMed  Google Scholar 

  20. Cefalu CA. Is bone mineral density predictive of fracture risk reduction? Curr Med Res Opin. 2004;20:341–9.

    Article  PubMed  Google Scholar 

  21. Speroff L, Darney PD. Special uses of oral contraception. In: A clinical guide for contraception. Philadelphia. Lippincott Williams & Wilkins, 2005, p 144, PA

  22. Mishell Jr DR. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med. 1996;41:381–90.

    PubMed  CAS  Google Scholar 

  23. Speroff L, Darney PD. Implant contraception. In: A Clinical Guide for Contraception. Philadelphia. PA: Lippincott Williams & Wilkins, 2005, p 166

  24. Speroff L, Darney PD. Intrauterine contraception. In: A Clinical Guide for Contraception. Philadelphia. PA: Lippincott Williams & Wilkins, 2005, p 228

  25. Luukkainen T, Lahteenmaki P, Toivonen J. Levonorgestrel-releasong intrauterine device. Ann Med. 1990;22:85–90.

    Article  PubMed  CAS  Google Scholar 

  26. Beerthuizen R, Van Beek A, Massai R, Makarainen L, Hout J, Bennink HC. Bone mineral density during long-term use of the progestagen contraceptive implant Implanon compared to a nonhormonal method of contraception. Hum Reprod. 2000;15:118–22.

    Article  PubMed  CAS  Google Scholar 

  27. Speroff L, Darney PD. Oral contraception. In: A Clinical Guide for Contraception. Philadelphia. PA: Lippincott Williams & Wilkins, 2005, p 41

  28. Vandever MA, Kuehl TJ, Sulak PJ, Witt I, Coffee A, Wincek TJ, et al. Evaluation of pituitary-ovarian axis suppression with three oral contraceptive regimens. Contraception. 2008;77:162–70.

    Article  PubMed  CAS  Google Scholar 

  29. Westhoff C, Torgal AH, Mayeda ER, Satnczyk FZ, Lerner JP, Benn EK, et al. Ovarian suppression in normal-weight and obese women during oral contraceptive use: a randomized controlled trial. Obstet Gynecol. 2010;116:275–83.

    Article  PubMed  Google Scholar 

  30. Tolaymat LL, Kaunitz AM. Long acting contraceptives in adolescents. Curr Opin Obstet Gynecol. 2007;19:453–60.

    Article  PubMed  Google Scholar 

  31. Kaunitz AM. Long acting hormonal contraceptives indispensable in preventing teen pregnancy. J Adolesc Health. 2007;40:1–3.

    Article  PubMed  Google Scholar 

  32. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatrc Adolesc Med. 2005;159:139–44.

    Article  Google Scholar 

  33. Rosenberg L, Zhang Y, Constant D, Cooper D, Kalla AA, Micklesfield L, et al. Bone status after cessation of use of injectable progestin contraceptives. Contraception. 2007;76:425–31.

    Article  PubMed  CAS  Google Scholar 

  34. Cromer BA, Bonny AE, Stager M, Lazebnik R, Rome E, Ziegler J, et al. Bone mineral density in adolescent females using injectable or oral contraceptives: a 24-month prospective study. Fertil Steril. 2008;90:2060–7.

    Article  PubMed  Google Scholar 

  35. Berenson AB, Rahman M, Breitkopf CR, Bi LX. Effects of depot medroxyprogesterone acetate and 20-microgram oral contraceptives on bone mineral density. Obstet Gynecol. 2008;112:788–99.

    Article  PubMed  Google Scholar 

  36. Harel Z, Johnson CC, Gold MA, Cromer B, Peterson E, Burkman R, et al. Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections. Contraception. 2010;81:281–91.

    Article  PubMed  CAS  Google Scholar 

  37. Cundy T, Evans M, Roberts H, Wattie D, Ames R, Reid IR. Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ. 1991;303:13–6.

    Article  PubMed  CAS  Google Scholar 

  38. Cundy T, Cornish J, Evans MC, Roberts H, Reid IR. Recovery of bone density in women who stop using medroxyprogesterone acetate. BMJ. 1994;308:247–8.

    PubMed  CAS  Google Scholar 

  39. Scholes D, Lacroix AZ, Ott SM, Ichikawa LE, Barlow WE. Bone mineral density in women using depot medroxyprogesterone acetate for contraception. Obstet Gynecol. 1999;93:233–8.

    Article  PubMed  CAS  Google Scholar 

  40. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology. 2002;13:749.

    Article  Google Scholar 

  41. Kaunitz AM, Miller PD, Rice VM, Ross D, McClung MR. Bone mineral density in women aged 25–35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception. 2006;74:90–9.

    Article  PubMed  CAS  Google Scholar 

  42. Kaunitz AM, Arias R, McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception. 2008;77:67–76.

    Article  PubMed  CAS  Google Scholar 

  43. Gai L, Zhang J, Zhang H, Gai P, Zhou L, Liu Y. The effect of depot medroxyprogesterone acetate (DMPA) on bone mineral density (BMD) and evaluating changes in BMD after discontinuation of DMPA in Chinese women of reproductive age. Contraception: article in press, published online September 14, 2010

  44. Gbolade B, Ellis S, Murby B, Randall S, Kirkman R. Bone density in long term users of depot medroxyprogesterone acetate. Br J Obstet Gynaecol. 1998;105:790–4.

    Article  PubMed  CAS  Google Scholar 

  45. Tang OS, Tang G, Yip P, Li B, Fan S. Long-term depot medroxyprogesterone acetate and bone mineral density. Contraception. 1999;59:25–9.

    Article  PubMed  CAS  Google Scholar 

  46. Tang OS, Tang G, Yip PS, Li B. Further evaluation on long-term depot-medroxyprogesterone acetate use and bone mineral density: a longitudinal cohort study. Contraception. 2000;62:161–4.

    Article  PubMed  CAS  Google Scholar 

  47. Besinska ME, Smit JA, Kleinschmidt I, Farley TM, Mbatha F. Bone mineral density in women aged 40–49 years using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraceptives for contraception. Contraception. 2005;71:170–5.

    Article  CAS  Google Scholar 

  48. Cundy T, Cornish J, Roberts H, Reid IR. Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception. Am J Obstet Gynecol. 2002;186:978–83.

    Article  PubMed  CAS  Google Scholar 

  49. Sanches L, Marchi NM, Castro S, Juliato CT, Villarroel M, Bahamondes L. Forearm bone density in postmenopausal former users of depot medroxyprogesterone acetate. Contraception. 2008;78:365–9.

    Article  PubMed  CAS  Google Scholar 

  50. Viola AS, Castro S, Marchi NM, Bahamondes BV, Viola CF, Bahamondes L. Long-term assessment of forearm bone mineral density in postmenopausal former users of depot medroxyprogesterone acetate. Contraception, In press

  51. Orr-Walker BJ, Eveans MC, Ames RW, Clearwater JM, Cundy T, Reid IR. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin Endocrinol. 1998;49:615–8.

    Article  CAS  Google Scholar 

  52. Harkins GJ, Davis GD, Dettori J, Hibbert ML, Hoyt RA. Decline in bone mineral density with stress fractures in a woman on depot medroxyprogesterone acetate. A case report. J Reprod Med. 1999;44:309–12.

    PubMed  CAS  Google Scholar 

  53. Searle ES. Spinal fracture in a young Depo-Provera user. J Fam Plann Reprod Health Care. 2005;31:255.

    Article  PubMed  Google Scholar 

  54. Watson KC, Lentz MJ, Cain KC. Associations between fracture incidence and use of depot medroxyprogesterone acetate and antiepileptic drugs in women with developmental disabilities. Womens Health Issues. 2006;16:346–52.

    Article  PubMed  Google Scholar 

  55. Lappe JM, Stegman MR, Recker RR. The impact of lifestyle factors on stress fractures in female army recruits. Osteoporos Int. 2001;12:35–42.

    Article  PubMed  CAS  Google Scholar 

  56. Vestergaard P, Rejnmark L, Mosekilde L. The effects of depot medroxyprogesterone acetate and intrauterine device use on fracture risk in Danish women. Contraception. 2008;78:459–64.

    Article  PubMed  CAS  Google Scholar 

  57. Meier C, Brauchli YB, Jick SS, Kraenzlin ME, Meier CR. Use of depot medroxyprogesterone acetate and fracture risk. J Clin Endocrin Metab. 2010;95:4909–16.

    Article  CAS  Google Scholar 

  58. Polatti F, Perotti F, Filippa N, Gallina D, Nappi RE. Bone mass and long-term monophasic oral contraceptive treatment in young women. Contraception. 1995;51:221–4.

    Article  PubMed  CAS  Google Scholar 

  59. Cromer BA, Blair JM, Mahan JD, Zibners L, Naumovski Z. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr. 1996;129:671–6.

    Article  PubMed  CAS  Google Scholar 

  60. Cromer BA, Stager M, Bonny A, Lazebnik R, Rome E, Ziegler J, et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort or adolescent girls. J Adolesc Health. 2004;35:434–41.

    Article  PubMed  Google Scholar 

  61. Lara-Torre E, Edwards CP, Perlman S, Hertweck SP. Bone mineral density in adolescent females using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol. 2004;17:17–21.

    Article  PubMed  Google Scholar 

  62. Hartard M, Kleinmond C, Wiseman M, Weissenbacher ER, Felsenberg D, Erben RG. Detrimental effect of oral contraceptives on parameters of bone mass and geometry in a cohort of 248 young women. Bone. 2007;40:444–50.

    Article  PubMed  CAS  Google Scholar 

  63. Pikkaranainen E, Lehtonen-Veromaa M, Mottonen T, Kautiainen H, Viikara J. Estrogen-progestin contraceptive use during adolescence prevents bone mass acquisition: a 4-year follow-up study. Contraception. 2008;78:226–31.

    Article  CAS  Google Scholar 

  64. Beksinska ME, Kleinschmidt I, Smit JA, Farley TM. Bone mineral density in a cohort of adolescents during use of norethondrone enanthate, depot-medroxyprogesterone acetate or combined oral contraceptives and after discontinuation of norethisterone enanthate. Contraception. 2009;79:345–9.

    Article  PubMed  CAS  Google Scholar 

  65. Nappi C, Di Spiezio SA, Acunzo G, Bifulco G, Tommaselli GA, Guida M, et al. Effects of a low-dose and ultra-low-dose combined contraceptive use on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study. Contraception. 2003;67:355–9.

    Article  PubMed  CAS  Google Scholar 

  66. Gargano V, Massaro M, Morra I, Formisano C, Di Carlo C, Nappi C. Effects of two low-dose combined oral contraceptives containing drospirenone on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study. Contraception. 2008;78:10–5.

    Article  PubMed  CAS  Google Scholar 

  67. Lattakova M, Borovsky M, Payer J, Killinger Z. Oral contraception usage in relation to bone mineral density and boner turnover in adolescent girls. Eur J Contracept Reprod Health Care. 2009;14:207–14.

    Article  PubMed  CAS  Google Scholar 

  68. Scholes D, Ichikawa L, LaCroix AZ, Spangler L, Beasley JM, Reed S, et al. Oral contraceptive use and bone density in adolescent and young adult women. Contraception. 2010;81:35–40.

    Article  PubMed  CAS  Google Scholar 

  69. Nappi C, Di Spiezio SA, Greco E, Tommaselli GA, Giordano E, Guida M. Effects of an oral contraceptive containing drospirenone on bone turnover and bone mineral density. Obstet Gynecol. 2005;105:53–60.

    Article  PubMed  CAS  Google Scholar 

  70. Reed SD, Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Longitudinal changes in bone density in relation to oral contraceptive use. Contraception. 2003;68:177–82.

    Article  PubMed  CAS  Google Scholar 

  71. Berenson AB, Radecki CM, Grady JJ, Rickert VI, Thomas A. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstet Gynecol. 2001;98:576–82.

    Article  PubMed  CAS  Google Scholar 

  72. Berenson AB, Breitkopf CR, Grady JJ, Rickert VI, Thomas A. Effects of hormonal contraception on bone density after 24 months of use. Obstet Gynecol. 2004;103:899–906.

    Article  PubMed  CAS  Google Scholar 

  73. Cobb KL, Kelsey JL, Sidney S, Ettinger B, Lewis CE. Oral contraceptives and bone mineral density in white and black women in CARDIA. Coronary Risk Development in Young Adults. Osteoporos Int. 2002;13:893–900.

    Article  PubMed  CAS  Google Scholar 

  74. Mazess RB, Barden HS. Bone density in premenopausal women: effects of age, dietary intake, physical activity, smoking, and birth control pills. Am J Clin Nutr. 1991;53:132–42.

    PubMed  CAS  Google Scholar 

  75. Paoletti AM, Orru M, Lello S, Floris S, Ranuzzi F, Etzi R, et al. Short-term variations in bone remodeling markers of an oral contraception formulation containing 3 mg of drospirenone plus 30 microg of ethinyl estradiol: observational study in young postadolescent women. Contraception. 2004;70:293–8.

    Article  PubMed  CAS  Google Scholar 

  76. Volpe A, Amram A, Cagnacci A, Battaglia C. Biochemical aspects of hormonal contraception: effects on bone metabolism. Eyr J Contracept Reprod Health Care. 1997;2:123–6.

    Article  CAS  Google Scholar 

  77. Shargil AA. Hormone replacement therapy in perimenopausal women with a triphasic contraceptive compound; a three-year prospective study. Int J Fertil. 1985;30:18–28.

    Google Scholar 

  78. Gambacciani M, Ciaponi M, Cappagli B, Benussi C, Genazzani AR. Longitudinal evaluation of perimenopausal femoral bone loss: effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism. Osteoporos Int. 2000;11:544–8.

    Article  PubMed  CAS  Google Scholar 

  79. Gambacciani M, Cappagli B, Ciaponi M, Benussi C, Genazzani AR. Hormone replacement therapy in perimenopause: effect of a low dose oral contraceptive preparation on bone quantitative ultrasound characteristics. Menopause. 1999;6:43–8.

    PubMed  CAS  Google Scholar 

  80. Gambacciani M, Spinetti A, Cappagli B, Taponeco F, Maffei S, Piaggesi L, et al. Hormone replacement therapy in perimenopausal women with a low dose oral contraceptive preparation: effects on bone mineral density and metabolism. Maturitas. 1994;19:125–31.

    Article  PubMed  CAS  Google Scholar 

  81. Gambacciani M, Spinetti A, Taponeco F, Cappagli B, Piaggesi L, Fioretti P. Longitudinal evaluation of perimenopausal vertebral bone loss: effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism. Obstet Gynecol. 1994;83:392–6.

    PubMed  CAS  Google Scholar 

  82. Gambacciani M, Cappagli B, Lazzarini V, Ciaponi M, Fruzzetti F, Genazzani AR. Longitudinal evaluation of perimenopausal bone loss: effects of different low dose oral contraceptive preparations on bone mineral density. Maturitas. 2006;54:176–80.

    Article  PubMed  CAS  Google Scholar 

  83. Enzelsberger H, Metka M, Heytmanek G, Schurz B, Kurz C, Kusztrich M. Influence of oral contraceptive use on bone density in climacteric women. Maturitas. 1988;9:375–8.

    Article  PubMed  CAS  Google Scholar 

  84. Tuppurainen M, Kroger H, Saarikoski S, Honkanen R, Alhava E. The effect of previous oral contraceptive use on bone mineral density in perimenopausal women. Osteoporos Int. 1994;4:93–8.

    Article  PubMed  CAS  Google Scholar 

  85. Masaryk P, Lunt M, Benevolenskaya L, Cannata J, Dequeker J, Dohenhof C, et al. Effects of menstrual history and use of medications on bone mineral density: the EVOS study. Calcif Tissue Int. 1998;63:271–6.

    Article  PubMed  CAS  Google Scholar 

  86. Fortney JA, Feldblum PJ, Talmage RV, Zhang J, Godwin SE. Bone mineral density and history of oral contraceptive use. J Reprod Med. 1994;39:105–9.

    PubMed  CAS  Google Scholar 

  87. Volpe A, Silferi M, Genazzani AD, Genazzani AR. Contraception in olsder women. Contraception. 1993;47:229–39.

    Article  PubMed  CAS  Google Scholar 

  88. Michaelsson K, Baron JA, Farahmand BY, Persson I, Ljunghall S. Oral-contraceptive use and risk of hip fracture: a case-control study. Lancet. 1999;353:1481–4.

    Article  PubMed  CAS  Google Scholar 

  89. Barad D, Kooperberg C, Wactawski-Wende J, Liu J, Hendrix SL, Watts NB. Prior oral contraception and postmenopausal fracture: a Women’s Health Initiative observational cohort. Fertil Steril. 2005;84:374–83.

    Article  PubMed  Google Scholar 

  90. Massai R, Makarainen L, Kuukankorpi A, Duijkers I, Dieben T. The combined contraceptive vaginal ring and bone density in healthy pre-menopausal women. Hum Reprod. 2005;20:2764–8.

    Article  PubMed  CAS  Google Scholar 

  91. Massaro M, Di Carlo C, Gargano V, Formisano C, Bifulco G, Nappi C. Effects of the contraceptive patch and the vaginal ring on bone metabolism and bone mineral density: a prospective, controlled, randomized study. Contraception. 2010;81:209–14.

    Article  PubMed  CAS  Google Scholar 

  92. Harel Z, Riggs S, Vaz R, Flanagan P, Harel D, Machan JT. Bone accretion in adolescents using the combined estrogen and progestin transdermal contraceptive method Ortho Evra: a pilot study. J Pediatr Adolesc Gynecol. 2010;23:23–31.

    Article  PubMed  Google Scholar 

  93. Caird LE, Reid-Thomas V, Hannan WJ, Gow S, Glasier AF. Oral progestogen-only contraception may protect against loss of bone mass in breast-feeding women. Clin Endocrinol. 1994;41:739–45.

    Article  CAS  Google Scholar 

  94. Wei S, Jones G, Thomson R, Dwyer T, Venn A. Oral contraceptive use and bone mass in women aged 26–36 years. Osteoporos Int: published online February 27, 2010.

  95. Bahamondes L, Espejo-Arce X, Hidalgo MM, Hidalgo-Regina C, Teatin-Juliato C, Petta CA. A cross-sectional study of the forearm bone density of long-term users of levonorgestrel-releasing intrauterine system. Hum Reprod. 2006;21:1316–9.

    Article  PubMed  CAS  Google Scholar 

  96. Bahamondes MV, Monteiro I, Castro S, Espejo-Arce X, Bahamondes L. Prospective study of the forearm bone mineral density of long-term users of the levonorgestrel-releasing intrauterine system. Hum Reprod. 2010;25:1158–64.

    Article  PubMed  CAS  Google Scholar 

  97. Bahamondes L, Monteiro-Dantas C, Espejo-Arce X, Dos Santas Fernandes AM, Lui-Filho JF, Perrotti M, et al. A prospective study of the forearm bone density of users of etonogesterl- and levonorgestrel-releasing contraceptive implants. Hum Reprod. 2006;21:466–70.

    Article  PubMed  CAS  Google Scholar 

  98. Pongsatha S, Ekmahachai M, Suntornlimsiri N. Bone mineral density in women using the subdermal contraceptive implant Implanon for at least 2 years. Int J Gynecol Obstet. 2010;109:223–5.

    Article  CAS  Google Scholar 

  99. Kalkwarf HJ, Specker BL. Bone mineral loss during lactation and recovery after weaning. Obstet Gynecol. 1995;86:26–32.

    Article  PubMed  CAS  Google Scholar 

  100. Polatti F, Capuzzo E, Viazzo F, Colleoni R, Klersy C. Bone mineral density changes during and after lactation. Obstet Gynecol. 1999;94:52–6.

    Article  PubMed  CAS  Google Scholar 

  101. Hayslip CC, Klein TA, Wray HL, Duncan WE. The effects of lactation on bone mineral content in healthy postpartum women. Obstet Gynecol. 1989;73:588–92.

    PubMed  CAS  Google Scholar 

  102. Karlsson C, Obrant KJ, Karlsson M. Pregnancy and lactation confer reversible bone loss in humans. Osteoporosis Int. 2001;12:828–34.

    Article  CAS  Google Scholar 

  103. Chantry CJ, Auinger P, Byrd RS. Lactation among adolescent mothers and subsequent bone mineral density. Arch Pediatrc Adolesc Med. 2004;158:650–71.

    Article  Google Scholar 

  104. Honda A, Kurabayashi T, Yahata T, Tomita M, Takakuwa K, Tanaka K. Lumbar bone mineral density changes during pregnancy and lactation. Int J Gynecol Obstet. 1998;63:253–8.

    Article  CAS  Google Scholar 

  105. Lopez JM, Gonzalez G, Reyes V, Campino C, Diaz S. Bone turnover and density in healthy women during breastfeeding and after weaning. Osteoporosis Int. 1996;6:153–9.

    Article  CAS  Google Scholar 

  106. Sowers M, Corton G, Shapiro B, Jannausch ML, Crutchfield M, Smith ML, et al. Changes in bone density with lactation. JAMA. 1993;269:3130–5.

    Article  PubMed  CAS  Google Scholar 

  107. Lenora J, Lekamwasam S, Karlsson MK. Effects of multiparity and prolonged breast-feeding on maternal bone mineral density: a community-based cross-sectional study. BMC Women’s Health. 2009;9:19.

    Article  PubMed  Google Scholar 

  108. Schnatz PF, Barker KG, Marakovits KA, O’Sullivan DM. Effects of age at first pregnancy and breast-feeding on the development of postmenopausal osteoporosis. Menopause. 2010;17:1161–6.

    Article  PubMed  Google Scholar 

  109. US Food and Drug Administration. Black box warning added concerning long-term use of Depo-Provera Contraceptive Injection, 2004

  110. Paschall S, Kaunitz AM. Depo-Provera and skeletal health: a survey of Florida obstetrics and gynecologist physicians. Contraception. 2008;78:370–6.

    Article  PubMed  CAS  Google Scholar 

  111. World Health Organization. WHO statement on hormonal contraception and bone health. WHO Epidemiological Record No 35. Geneva, Switzerland: World Health Organization 2005

  112. Cromer BA, Scholes D, Berenson A, Cundy T, Clark MK, Kaunitz AM, et al. Depot medroxyprogesterone acetate and bone mineral density in adolescent—the Black Box Warning: a position paper of the Society for Adolescent Medicine. J Adolesc Health. 2006;39:296–301.

    Article  PubMed  Google Scholar 

  113. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG Committee Opinion No. 415: depot medroxyprogesterone acetate and bone effects. Obstet Gynecol. 2008;112:727–30.

    Article  Google Scholar 

  114. Black A. Canadian contraception consensus: update on depot medroxyprogesterone acetate (DMPA). J Obstet Gynaecol Can. 2006;28:305–13.

    PubMed  Google Scholar 

  115. WHO. Medical eligibility criteria for contraceptive use. 4th ed. Geneva: WHO; 2009.

    Google Scholar 

  116. CDC. Medical eligibility criteria contraceptive use, 2010. Adapted from the WHO Medical eligibility criteria for contraceptive use. 4th ed. Atlanta: CDC; 2010.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, The Ohio State University, 395 W 12th Ave, Rm 503, Columbus, OH, 43210, USA

    Michelle M. Isley

  2. Department of Obstetrics and Gynecology, University of Florida College of Medicine-Jacksonville, Jacksonville, FL, 32209, USA

    Andrew M. Kaunitz

Authors
  1. Michelle M. Isley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew M. Kaunitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michelle M. Isley.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Isley, M.M., Kaunitz, A.M. Update on hormonal contraception and bone density. Rev Endocr Metab Disord 12, 93–106 (2011). https://doi.org/10.1007/s11154-011-9180-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11154-011-9180-6

Keywords

Search

Navigation